Israeli Biotech Startup SpliSense Raises $28M For Cystic Fibrosis Therapeutics
Israeli biotech startup SpliSense, a pre-clinical developer of mRNA-altering therapies for cystic fibrosis (CF) and other genetic pulmonary diseases, has announced the closure of a $28.5 million Series B funding round with investors that include Orbimed, the Israel Biotech Fund, Biotel Limited, Integra Holdings, a major shareholder, and the US Cystic Fibrosis Foundation.
Founded in 2016, SpliSense created a platform that harnesses Anti Sense Oligonucleotides (ASO), small pieces of DNA or RNA that can bind to specific molecules of RNA, for the treatment of genetic diseases such as CF, a genetic disease that leads to respiratory infections and disabilities. CF is caused by mutations in the Cystic Fibrosis Transmembrane conductance Regulator (CFTR) gene, leading to dysfunctional CFTR proteins.